Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Pioneer Research Solutions

Neither a doctor nor a teaching hospital

Research payments

$2,398,924

32 payments

Through program year 2025, Pioneer Research Solutions is reported as receiving $2,398,924 in research payments, across 32 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $75,110 6
2024 Research $2,206,671 4
2021 Research $36,815 8
2020 Research $78,276 12
2019 Research $2,051 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $2,202,053 3 payments
  2. Ironwood Pharmaceuticals, Inc $89,537 12 payments
  3. GlaxoSmithKline, LLC. $75,110 6 payments
  4. Sanofi US Services Inc. $18,506 7 payments
  5. Pfizer Inc. $8,600 2 payments
  6. Novartis Pharmaceuticals Corporation $4,618 1 payment
  7. Merck Sharp & Dohme Corporation $500 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. P4 Uncontrolled Gout FORWARD II $2,180,924 1 payment
  2. C3718-302 $89,537 12 payments
  3. A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Eval $75,110 6 payments
  4. ASTRO P3 AD Adolescent Mono $21,129 2 payments
  5. Qualitative Interviews With Patients and Caregivers to Support Pfizers Sickle Cell Disease Clinical Development Program $8,600 2 payments
  6. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $8,400 1 payment
  7. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs) $5,452 1 payment
  8. A 5-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Assessing the Efficacy, Safety, and Tolerability of Intra-Articular Regimens of Lna043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis $4,618 1 payment
  9. A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr $2,051 2 payments
  10. A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder $1,965 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record